PF-06647020, a humanized anti-PTK7 ADC, has been developed and is currently being evaluated in clinical trials for the treatment of ovarian cancer, triple-negative breast cancer, and non-small cell lung cancer [65,66]. Here, PTK7 is linked to triple-negative breast carcinoma.